Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid

Nature Neuroscience

Volumn 16, Issue 11, 2013, Pages 1652-1661

  Justinova, Zuzana ^a,b   Mascia, Paola ^a,h   Wu, Hui Qiu ^b   Secci, Maria E ^a   Redhi, Godfrey H ^a   Panlilio, Leigh V ^a   Scherma, Maria ^c   Barnes, Chanel ^a   Parashos, Alexandra ^a   Zara, Tamara ^c   Fratta, Walter ^c   Solinas, Marcello ^d,e   Pistis, Marco ^c,f   Bergman, Jack ^g   Kangas, Brian D ^g   Ferré, Sergi ^a   Tanda, Gianluigi ^a   Schwarcz, Robert ^b   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d INSERM   (France)

^e UNIVERSITÉ DE POITIERS   (France)

^f CNR   (Italy)

^g MCLEAN HOSPITAL   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; BENZENESULFONAMIDE DERIVATIVE; BUNGAROTOXIN RECEPTOR; CANNABINOID; CANNABIS; DOPAMINE; DRONABINOL; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ABSTINENCE; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; BRAIN REGION; CANNABIS ADDICTION; CONTROLLED STUDY; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; MALE; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE; REWARD; SQUIRREL MONKEY; WORKING MEMORY;

ANALGESICS; ANIMALS; BENZOXAZINES; BRAIN; CANNABINOID RECEPTOR AGONISTS; CONDITIONING, OPERANT; CUES; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG-SEEKING BEHAVIOR; KYNURENIC ACID; MALE; MEMORY, SHORT-TERM; MORPHOLINES; NAPHTHALENES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RECURRENCE; REINFORCEMENT (PSYCHOLOGY); SAIMIRI; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; SULFONAMIDES; THIAZOLES; TIME FACTORS; WAKEFULNESS;

EID: 84886950138     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3540     Document Type: Article

References (59)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Rockville, Maryland, USA, 2010
2. Gardner, E.L. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol. Biochem. Behav. 81, 263-284 (2005
3. Solinas, M., Goldberg, S.R. & Piomelli, D. The endocannabinoid system in brain reward processes. Br. J. Pharmacol. 154, 369-383 (2008
4. Diana, M., Melis, M. & Gessa, G.L. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur. J. Neurosci. 10, 2825-2830 (1998
5. French, E.D., Dillon, K. & Wu, X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8, 649-652 (1997
6. Chen, J.P. et al. Delta 9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl.) 102, 156-162 (1990
7. Tanda, G., Pontieri, F.E. & Di Chiara, G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048-2050 (1997
8. Dani, J.A. & Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 47, 699-729 (2007
9. Fu, Y., Matta, S.G., Gao, W., Brower, V.G. & Sharp, B.M. Systemic nicotine stimulates dopamine release in nucleus accumbens: Re-evaluation of the role of N-methyl-D-Aspartate receptors in the ventral tegmental area. J. Pharmacol. Exp. Ther. 294, 458-465 (2000
10. Kaiser, S. & Wonnacott, S. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58, 312-318 (2000
11. Solinas, M. et al. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J. Neurosci. 27, 5615-5620 (2007
12. Weinstein, A.M. & Gorelick, D.A. Pharmacological treatment of cannabis dependence. Curr. Pharm. Des. 17, 1351-1358 (2011
13. Arias, H.R. et al. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int. J. Biochem. Cell Biol. 41, 1441-1451 (2009
14. Roegge, C.S. & Levin, E.D. Nicotinic receptor antagonists in rats. in Animal Models of Cognitive Impairment (eds. Levin, E.D. & Buccafusco, J.J.) (CRC, Boca Raton, Florida, USA, 2006
15. Arias, H.R. Positive and negative modulation of nicotinic receptors. Adv. Protein Chem. Struct. Biol. 80, 153-203 (2010
16. Bertrand, D. et al. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: Ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol. Pharmacol. 74, 1407-1416 (2008
17. Christopoulos, A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198-210 (2002
18. Perkins, M.N. & Stone, T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184-187 (1982
19. Kiss, C. et al. Kynurenate production by cultured human astrocytes. J. Neural Transm. 110, 1-14 (2003
20. Moroni, F., Russi, P., Lombardi, G., Beni, M. & Carla, V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51, 177-180 (1988
21. Kessler, M., Terramani, T., Lynch, G. & Baudry, M. A glycine site associated with N-methyl-D-Aspartic acid receptors: Characterization and identification of a new class of antagonists. J. Neurochem. 52, 1319-1328 (1989
22. Alkondon, M. et al. Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci. 24, 4635-4648 (2004
23. Hilmas, C. et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-Alpha7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 21, 7463-7473 (2001
24. Lopes, C. et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7. * nicotinic receptors. J. Pharmacol. Exp. Ther. 322, 48-58 (2007
25. Amori, L. et al. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159, 196-203 (2009
26. Wu, H.Q. et al. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J. Mol. Neurosci. 40, 204-210 (2010
27. Zmarowski, A. et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci. 29, 529-538 (2009
28. Carpenedo, R. et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 13, 2141-2147 (2001
29. Rassoulpour, A., Wu, H.Q., Ferre, S. & Schwarcz, R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 93, 762-765 (2005
30. Schwarcz, R., Bruno, J.P., Muchowski, P.J. & Wu, H.Q. Kynurenines in the mammalian brain: When physiology meets pathology. Nat. Rev. Neurosci. 13, 465-477 (2012
31. Justinova, Z., Tanda, G., Redhi, G.H. & Goldberg, S.R. Self-Administration of delta9-Tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl.) 169, 135-140 (2003
32. Justinova, Z. et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry 64, 930-937 (2008
33. Amaral, M. et al. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496, 382-385 (2013
34. Moroni, F. Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375, 87-100 (1999
35. Grégoire, L. et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 186, 161-167 (2008
36. Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874 (2011
37. Fukui, S., Schwarcz, R., Rapoport, S.I., Takada, Y. & Smith, Q.R. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J. Neurochem. 56, 2007-2017 (1991
38. Turski, W.A., Gramsbergen, J.B., Traitler, H. & Schwarcz, R. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J. Neurochem. 52, 1629-1636 (1989
39. Turski, W.A. & Schwarcz, R. On the disposition of intrahippocampally injected kynurenic acid in the rat. Exp. Brain Res. 71, 563-567 (1988
40. Uwai, Y., Honjo, H. & Iwamoto, K. Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. Pharmacol. Res. 65, 254-260 (2012
41. Röver, S., Cesura, A.M., Huguenin, P., Kettler, R. & Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-Affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40, 4378-4385 (1997
42. Hurst, R.S. et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: In vitro and in vivo characterization. J. Neurosci. 25, 4396-4405 (2005
43. Chess, A.C., Simoni, M.K., Alling, T.E. & Bucci, D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 33, 797-804 (2007
44. Pocivavsek, A. et al. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36, 2357-2367 (2011
45. Navarrete, M. & Araque, A. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126 (2010
46. Pistis, M., Porcu, G., Melis, M., Diana, M. & Gessa, G.L. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur. J. Neurosci. 14, 96-102 (2001
47. Pistis, M., Muntoni, A.L., Pillolla, G. & Gessa, G.L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: An in vivo electrophysiological study. Eur. J. Neurosci. 15, 1795-1802 (2002
48. Panlilio, L.V. et al. Combined effects of THC and caffeine on working memory in rats. Br. J. Pharmacol. 165, 2529-2538 (2012
49. Le Foll, B., Gorelick, D.A. & Goldberg, S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl.) 205, 171-174 (2009
50. Cozzi, A., Carpenedo, R. & Moroni, F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-Alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19, 771-777 (1999
51. Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates (Academic, San Diego, 1998
52. Fadda, P., Scherma, M., Fresu, A., Collu, M. & Fratta, W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50, 1-6 (2003
53. Fattore, L. et al. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-Administering heroin or WIN 55,212-2. Eur. J. Neurosci. 25, 2191-2200 (2007
54. Goldberg, S.R. Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-Amphetamine injection in the squirrel monkey. J. Pharmacol. Exp. Ther. 186, 18-30 (1973
55. Panlilio, L.V., Yasar, S., Thorndike, E.B., Goldberg, S.R. & Schindler, C.W. Automatic recording of mediating behavior in delayed matching- and nonmatching-To-position procedures in rats. Psychopharmacology (Berl.) 214, 495-504 (2011
56. Kangas, B.D., Berry, M.S. & Branch, M.N. On the development and mechanics of delayed matching-To-sample performance. J. Exp. Anal. Behav. 95, 221-236 (2011
57. Kangas, B.D. & Bergman, J. A novel touch-sensitive apparatus for behavioral studies in unrestrained squirrel monkeys. J. Neurosci. Methods 209, 331-336 (2012
58. Solinas, M., Panlilio, L.V., Antoniou, K., Pappas, L.A. & Goldberg, S.R. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-Administration in rats. J. Pharmacol. Exp. Ther. 306, 93-102 (2003
59. Kangas, B.D. et al. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J. Pharmacol. Exp. Ther. 344, 561-567 (2013